Novel T cell receptor therapy shows early anti-tumor activity
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial.
Read Original Article: Novel T cell receptor therapy shows early anti-tumor activity »
